Efficacy and Safety of Iptacopan in Patients with Generalized Myasthenia Gravis: Study Design (P7-11.027)
This Phase III study aims to evaluate the efficacy and safety of iptacopan (LNP023) in patients with anti-acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) on stable standard of care (SOC) treatment.
Authors
- Srikanth Muppidi (ORCID: https://orcid.org/0000-0002-2773-2506)
- John Vissing (ORCID: https://orcid.org/0000-0001-6144-8544)
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Heinz Wiendl (ORCID: https://orcid.org/0000-0003-4310-3432)
- J. A. Howard (ORCID: https://orcid.org/0000-0001-5020-9687)
- Vera Bril (ORCID: https://orcid.org/0000-0002-5805-4883)
- Stephen Reddel (ORCID: https://orcid.org/0000-0002-0169-3350)
- S. Jevtic
- Arseniy Lavrov (ORCID: https://orcid.org/0000-0002-2360-2253)
- Bernd C. Kieseier
- Weihua Cao
Institutions
- Novartis (Switzerland) (CH)
- The University of Sydney (AU)
- University of Freiburg (DE)
- Toronto General Hospital (CA)
- Rigshospitalet (DK)
- Novartis (United Kingdom) (GB)
- National Hospital Organization Hanamaki Hospital (JP)
- Stanford University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211246
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39